Xeljanz

Tofacitinib Compared With Adalimumab in RA Study

Tofacitinib Compared With Adalimumab in RA Study

By

Pfizer has announced top-line results from its Phase 3B/4 study comparing treatment with Xeljanz to adalimumab in patients with moderate to severe rheumatoid arthritis.

Sign Up for Free e-Newsletters